Pfizer to present new drug data at ACR/ARHP 2014

Pfizer has announced that it will be presenting new drug data at the forthcoming annual meeting of the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP).

The conference will be held in Boston from November 14th to 19th and will see the company share research findings pertaining to several of its marketed and investigational medicines for inflammatory and immunological conditions.

A total of 21 abstracts, including additional clinical trial data and real-world analyses, will add to the body of evidence supporting the drug Xeljanz as a beneficial treatment option for adults with moderate to severe rheumatoid arthritis.

Additionally, efficacy results from a phase II study of an anti-IL-6 therapy for lupus will be shared, as well as phase I abstracts for two biosimilars that have since been moved to phase III compatibility trials.

Dr Steve Romano, senior vice-president and head of global medicines development for the Pfizer Global Innovative Pharmaceutical business, said: "Inflammation is one of the core research areas for Pfizer; our robust inflammation programme has spanned over 60 years and includes more than ten assets under investigation at various stages of development."

Last month, the company reported its financial results for the third quarter of 2014, during which it generated a revenue total of $12.4 billion (7.87 billion pounds).